Imatinib mesylate induced erythroderma

Indian Journal of Dermatology, Venereology and Leprology

Volumn 78, Issue 3, 2012, Pages 408-

  Sanghavi, Swapnil A ^a   Dongre, Atul M ^a   Khopkar, Uday S ^a  

^a KEM HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; DASATINIB; HYDROXYUREA; IMATINIB; PREDNISOLONE; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHEMA; ERYTHRODERMA; FEMALE; HUMAN; HUMAN TISSUE; INDIA; LETTER; RASH; SKIN BIOPSY; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; DERMATITIS, EXFOLIATIVE; DRUG ERUPTIONS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PYRIMIDINES;

EID: 84862080181     PISSN: 03786323     EISSN: 09733922     Source Type: Journal    
DOI: 10.4103/0378-6323.95491     Document Type: Letter

References (5)

1. Mathew T, Chandrashekar L, Pulimood S, Srivastava A. Imatinib induced erythroderma. Australas J Dermatol 2007;48:193-194
2. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3-7
3. Prabhash K, Biswas G, Prasad N, Karant N, Sastry PS, Parikh PM. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia. Indian J Dermatol Venereol Leprol 2006; 72:63-64
4. Nelson RP Jr, Cornetta K, Ward KE, Ramanuja S, Fausel C, Cripe LD. Desensitization to imatinib in patients with leukemia. Ann Allergy Asthma Immunol 2006; 97:216-222
5. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - A review on pharmacology, metabolism and side effects. Curr Drug Metab 2009;10:470-481